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Abstract: Short-chain quinones (SCQs) have been identified as potential drug candidates against
mitochondrial dysfunction, which is largely dependent on their reversible redox characteristics of the
active quinone core. We recently synthesized a SCQ library of > 148 naphthoquinone derivatives and
identified 16 compounds with enhanced cytoprotection compared to the clinically used benzoquinone
idebenone. One of the major drawbacks of idebenone is its high metabolic conversion in the liver, which
significantly restricts its therapeutic activity. Therefore, this study assessed the metabolic stability of
the 16 identified naphthoquinone derivatives 1–16 using hepatocarcinoma cells in combination with
an optimized reverse-phase liquid chromatography (RP-LC) method. Most of the derivatives showed
significantly better stability than idebenone over 6 hours (p < 0.001). By extending the side-chain
of SCQs, increased stability for some compounds was observed. Metabolic conversion from the
derivative 3 to 5 and reduced idebenone metabolism in the presence of 5 were also observed. These
results highlight the therapeutic potential of naphthoquinone-based SCQs and provide essential
insights for future drug design, prodrug therapy and polytherapy, respectively.
Keywords: mitochondrial dysfunction; idebenone; short-chain quinone; metabolic stability; HepG2
cell culture; reverse-phase liquid chromatography
1. Introduction
Mitochondrial dysfunction has been linked to a vast number of disorders ranging from primary
mitochondrial disorders such as Leber’s Hereditary Optical Neuropathy (LHON) to common diseases
associated with mitochondrial dysfunction such as diabetes [1–3]. Despite the large numbers of
patients that show mitochondrial dysfunction, there are hardly any drugs on the market that aim to
target mitochondrial function directly. This represents a significant unmet medical need and thus,
new drug candidates are needed that can be developed for this purpose. Potential drugs to protect
against mitochondrial dysfunction include short chain quinones (SCQs), which possess reversible
redox characteristics due to the quinone core [4–6]. The benzoquinone idebenone has shown some
limited activity to protect against vision loss and restore visual acuity in patients with LHON [7–9]. As
a consequence, it has been marketed in Europe for this purpose since 2015. In line with a protective
activity against mitochondrial dysfunction, it was recently suggested that idebenone could also have
anti-diabetic activity based on an insulin-sensitizing effect. This activity was suggested to be based on
its ability to inhibit the interaction of p52Shc with the insulin receptor [10].
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We recently reported the design and synthesis of a library of > 148 short-chain naphthoquinone
derivatives [11] that intended to overcome the known limitations of idebenone such as limited
bioactivation and rapid metabolic inactivation. From this panel, 16 SCQs (1-16, Table 1) showed
significantly improved cytoprotective activity in vitro compared to idebenone (p < 0.033) under
conditions of mitochondrial dysfunction [11]. The current study determined the in vitro metabolic
stability of 16 new SCQs to identify promising drug development candidates, before in vivo
pharmacokinetic studies in animal models can be initiated. A simple and efficient analytical
methodology was developed based on gradient-elution reverse-phase liquid chromatography (RP-LC)
in conjunction with sample preparation by acetonitrile (ACN) precipitation. This methodology allowed
for the required quantitation of SCQs at appropriate µM concentrations in the highly complex cell
culture media used in in vitro metabolic stability studies. The human hepatic cell line HepG2 was
previously described to mimic in vivo metabolism with liver-like conditions [12]. Although HepG2
cells show lower expression of metabolic enzymes compared to human liver samples ex vivo, this cell
line is perfectly suited and widely used for in vitro metabolic studies due to their high phenotypic
stability and unlimited availability, which provides a robust and reproducible test platform [13,14].
This study was essential to anticipate drug behavior (pharmacokinetics and metabolism) in vivo and
will aidin the development of the most promising compounds toward their clinical use.
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Table 1. Chemical structure, physical properties and in vitro efficacy of 16 novel short-chain quinones (SCQs) and the reference compound idebenone.
Compound ID Structure n R Formula Molecular Weight (g mol−1) LogP 1 LogD 2 In vitro Cytoprotection (%) 3
Idebenone
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2. Materials and Methods
2.1. Chemicals, Solutions, and Cells
Idebenone was provided by Santhera Pharmaceuticals (Pratteln, Switzerland) as a reference
compound. The novel SCQs (1–16) were synthesized as described previously [11]. LC-grade ACN was
purchased from VWR (Queensland, Australia). Purified water was from a Milli-Q system (Millipore,
MA, USA). Formic acid (FA), dimethylsulfoxide (DMSO), Dulbecco Modified Eagle Medium (DMEM,
D5523), and sodium bicarbonate were purchased from Sigma-Aldrich (New South Wales, Australia).
Fetal bovine serum (FBS) was purchased from SAFC Biosciences (Victoria, Australia). 0.25% Trypsin,
ethylenediaminetetraacetic acid (EDTA), and phosphate-buffered saline (PBS) tablets were purchased
from ThermoFisher Scientific (Victoria, Australia). The HepG2 cell line (HB-8065) was purchased from
ATCC (Manassas, VA, USA).
The stock solutions of each SCQ (100 mM) were prepared in DMSO and stored at −20 ◦C. Working
standard solutions of each SCQ (1.0 µM, 2.5 µM, 5.0 µM, 7.5 µM, 10.0 µM) were prepared by dilution
of the appropriate stock solutions with 25% ACN in water. DMEM cell culture media was prepared
according to the manufactures instructions and sterilized by filtration using 0.22 µm bottle top filters
(Corning, VIC, AU). DMEM was supplemented with FBS (10%), sodium bicarbonate (3.7 g L−1), and
stored at 4 ◦C. EDTA solution (0.5 mM, pH 8) was sterilized using 0.45 µm filters and stored at −20 ◦C.
2.2. RP-LC Instrumentation
The LogP values in Table 1 were predicted by the ChemDraw software (PerkinElmer, Waltham,
MA, USA). The LogP values suggested that these SCQs range from low (0.74) to intermediate (3.50)
lipophilicity. Thus, RP-LC was used for separation and quantitation. An UltiMate™ 3000 LC system
equipped with an UV detector (ThermoFisher Scientific, Victoria, Australia) was used. The system
operation, data acquisition and processing were performed using Chromeleon software (version 6.0,
ThermoFisher Scientific, Victoria, Australia). Analytical separations were carried out on an Acclaim™
Polar Advantage II RP-LC column (2.2 µm, 2.1 × 10 mm) at 25 ◦C. Mobile phase A and B was 0.1% FA
in purified water and 0.1% FA in ACN, respectively. Flow rate was 0.2 mL min−1 which gave a void
time (VT) of 1.2 min.
2.3. Metabolic Stability Study
2.3.1. Cell Culture
HepG2 cells were cultured in DMEM culture media in an atmosphere of 95% humidified air and
5% CO2 at 37 ◦C. Cells were passaged twice a week when reaching approximately 75% confluency. Cell
monolayers were washed with PBS once before harvested with 0.5 mL EDTA and 0.5 mL trypsin for
3.5 min and counted using a hemocytometer (Paul Marienfeld GmbH, Lauda-Königshofen, Germany).
Cells were routinely grown in 25 cm2 cell culture flasks (2 µm vent cap, Corning, Victoria, Australia)
with 2 × 106 cells seeded in 5 mL culture media. After thawing from liquid nitrogen storage, cells were
passaged for at least 2–3 weeks to reach steady cumulative growth rates before used for any experiments.
2.3.2. Cell Culture System Development
To effectively compare the metabolic stability of our novel SCQs to the reference compound
idebenone, a cell culture system had to be developed that would replicate the high metabolic conversion
of idebenone in the liver observed in vivo [15–17]. We therefore employed the hepatic cell line HepG2
to expose the test compounds to hepatic-like enzymatic activities [8]. In addition, the test concentration
for SCQs and idebenone had to take into consideration two opposing factors. On the one hand the
assay would need to contain sufficient test compound to maximize detection accuracy, on the other
hand, the concentration needed to be below the levels that might induce toxicity towards the cultured
cells. Based on previous data [11], no significant cell loss was observed when HepG2 cells were treated
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with most SCQs at a concentration of 200 µM for 24 h, which led us to select the lower concentration
of 40 µM as test concentration. In addition, to approach the metabolic conversion rates of idebenone
in vivo (t1/2 = 3 h at a single dose of 150 mg) [15], three different cell densities of 2.5 × 105, 5.0 × 105
and 1.0 × 106 cells in 2 mL media were initially evaluated using a single concentration of idebenone (40
µM). All three cell densities showed similar rates of metabolic conversion of idebenone with about
~50%, 76% and 87% metabolized drug after 2 h, 4 h and 6 h, respectively (Figures S1 and S2). We
therefore selected the lowest cell concentration (2.5 × 105 cells in 2 mL culture media) for this assay.
2.3.3. Sample Preparation
Log phase HepG2 cells were seeded at 2.5 × 105 cells well−1 in tissue culture-treated 6-well plates
(Corning, Victoria, Australia) and allowed to adhere overnight. After one day, the culture media was
replaced with fresh culture media (2 mL well−1) containing the test compounds (12 parallel wells per
SCQ). After incubation of cells with test compounds for up to 6 hours, the cell culture media containing
the residual SCQs was removed from the six-well plates. Then, 1 mL of cell culture media containing
each tested compound was collected at different time points (t = 0, 2 h, 4 h, 6 h). Several methods of
sample preparation were tested (e.g., dilution with organic solvents followed by evaporation) and
the most suited approach was identified. Each sample (1 mL) was mixed 1:1 with ACN, vortexed for
10 s, and then centrifuged at 2000× g for 10 min at 25 ◦C. 1 mL of each supernatant was diluted 1:1
in purified water and filtered using 0.45 µm filters prior to immediate analysis by RP-LC. The final
concentration of tested compounds for RP-LC analysis was ≤10 µM.
2.3.4. RP-LC Gradient Optimization and Analytical Performance
The RP-LC method was developed so that≤10 µM of each SCQ could be quantified with acceptable
repeatability (RSD%) and recovery (%). The mobile phase gradient was adjusted to generate a retention
time (RT) of all compounds between 3.00–9.05 min (Table S1). The final conditions included a gradient
flow of mobile phase B: 25% (same ACN% in the sample) for 2 min, 25–95% for 3 min, 95% for 4 min,
95–25% for 1 min, and 25% for 5 min (total run t = 15 min, including column post-conditioning). The
injection volume (2–20 µL) and detection wavelength (210 nm, 230 nm, 254 nm, 480 nm) were then
varied to optimize sensitivity, with 20 µL sample injection volume and detection at 210 nm identified as
ideal (Figure S3). Supplementary Table S1 summarizes the analytical figures of merit for the RP-LC of
all the compounds. Peak areas were found to be linear between 1–10 µM (Figure S4), with coefficients
of determination (R2) between 0.982–1.000. The limit of quantification (LOQ) of each compound
was established as 1 µM. RSD% (n = 3) at all concentrations (1.0 µM, 2.5 µM, 5.0 µM, 7.5 µM, and
10 µM) were between 0.4–7.6%. The percentage recovery (86.7–116.2%) was calculated by dividing
the concentrations found at t = 0 by 10 µM × 100%, with RSD% from 1.2–10.6%. The above values
for analytical figures of merit were considered acceptable for determining metabolic stability of the
compounds with concentrations ≤10 µM.
2.4. Statistical Analysis
GraphPad Prism (version 8.2.1, San Diego, CA, USA) was used to perform statistical analysis
between three or more groups through one-way or two-way ANOVA, respectively. The differences
were statistically significant when *** p < 0.001, ** p < 0.002, * p < 0.033.
3. Results and Discussion
3.1. Superior Metabolic Stability of UTAS SCQs
The recovery (%) of SCQs at t = 0 was very consistent by using precipitation with ACN (Figure 1).
Idebenone showed a significant reduction from t = 2 h onwards (p < 0.001) with ~27.3% remaining at t
= 6 h, which was consistent with its short half-life in vivo [15,18]. In contrast, of the 16 SCQs tested, six
(1, 2, 4, 5, 6 and 10) demonstrated supreme stability without a significant metabolic conversion over a
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period of 6 hours. Except for the sulfide derivative 16, most of the SCQs tested were significantly more
stable than idebenone (p < 0.001). At t = 4 h and 6 h, 15 SCQs (excluding 16) were significantly more
stable than idebenone (7 p < 0.033; others p < 0.001). Given that the enzymatic activities of HepG2 cells
are not comparable to those of fresh liver samples or other immortal cell lines such as HepaRG [13,14],
it has to be noted that HepG2 cells may not be sensitive enough to differentiate our best six SCQs 1, 2,
4, 5, 6 and 10. On the other hand, the comparative metabolic kinetics against idebenone using our
test system clearly demonstrated improved stability of the novel SCQs. Although the use of fresh
liver biopsies or different cell lines could have increased the speed of metabolic conversion in vitro,
it is important to point out that the kinetics achieved in our test system mirror the metabolism of
idebenone in patients with reported t1/2 of ~3 h in vivo (150 mg in a single dose) [15]. In addition, our
results highlight that the sulfide derivative 16 is not as competitive as the other amides 1–15, due to its
significantly reduced metabolic stability.
3.2. Increased Metabolic Stability by Carbon Chain Extension
Apart from the metabolic stability information provided by this assay, structure-metabolic stability
relationships were also obtained from the 16 compounds. The results indicate that the amide linkage is
very stable in general and instability occurs due to other substituents in the side chain. Comparing the
difference in amides, the data suggest that the carbon chain between the quinone core and the amide
linkage appears to increase metabolic stability (Figure 2). The tyramine derivative 7 was less stable,
likely due to the phenolic group, but the tyramine derivatives 8 and 9 showed increased metabolic
stability when the carbon chain was extended. 9 was significantly more stable than 8 over 4 h (p
< 0.002), 6 h (p < 0.033) and 7 at all time points (p < 0.033). This increased stability correlates with
increased lipophilicity, as it correlates to the log of distribution coefficient D (LogD) with increases
from 3.43, 3.87 to 4.31. Increased lipophilicity could either increase affinity to its target and to cellular
and mitochondrial membranes or at higher levels could reduce absorption due to a higher membrane
localization. In the current test system this would reduce interaction with metabolic enzymes located
in the cytoplasm but in vivo could reduce the absorption of the compounds or their blood-brain barrier
penetration. This connection between lipophilicity and metabolic stability was not observed for the
L-phenylalanine derivatives 5 and 6, which were two of the six most stable compounds.
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Figure 2. Comparison of metabolic stability and carbon c length between the quinone core and the
amide linkage for the structurally similar tyramine derivatives 7–9. Data was expressed as ean ± SEM
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3.3. Natural Enantiomer as a Prodrug Alternative
While no differences between the stable enantiomers 1 and 2 were observed, the naturally occurring
L-phenylaninol 3 was found much less stable than its unnatural D-enantiomer 4 (p < 0.001) (Figure 3).
This indicat s some sele tivity for th enz matic d grad tion of this enantiomer. In addition, the
L-phenylalaninol derivative 3 was much less stable than and its oxidized form, the L-phenylalanine
derivative 5 (p < 0.001). From the L-prolinol derivative 14 to its oxidized form, the L-proline derivative
15, the change in stability did not reach statistical significance. Initially, these two oxidized forms
were expected to be the metabolites of the two reduced forms, respectively. The peaks of the oxidized
forms were expected to be obs r ed and quantifi ble from chromatograms of the reduc d forms
according to releva t ret ntion times and linearity. So far, a ~10% conversion from the L-phenylalaninol
derivative 3 to the L-phenylalanine derivative 5 was detected according to the retention time, yet
conversion from 14 towards 15 was not detected at all. Furthermore, the conversion from 3 to 5 was
confirmed using mass spectrometry (Figure S5). In comparison with their enantiomers, no conversion
was detected for the unnatural D-phenylalaninol derivative 4 to its oxidized form D-phenylalanine
derivative UTAS#94 (Figure 3) [11], which was not cytoprotective enough to be selected for the current
study. This suggested that the reduced form 3 might be used as a prodrug for the oxidized form 5
as an alternative. Given the lower lipophilicity of 5 (LogD = 0.12), 3 (LogD = 3.10) could represent
a promising prodrug approach where upon crossing the blood-brain barrier, conversion from 3 to 5
would produce a highly active drug candidate to protect against mitochondrial dysfunction-induced
neurotoxicity and visual impairments.
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of 3 and 4, respectively. Data was expressed as mean ± SEM from three independent experiments, with
at least 3 data points each.
Pharmaceuticals 2020, 13, 29 10 of 12
3.4. Metabolically Stable UTAS SCQ as an Alternative for Polytherapy
The conversion from the L-phenylalaninol derivative 3 to the L-phenylalanine derivative 5
appeared to reach a plateau at ~10% conversion from t = 2 h and persisted for the entire test period
until t = 6 h. Guided by the superior stability of 5, we hypothesized that 5 might be a metabolic enzyme
inhibitor. A concentration series of the unstable reference SCQ idebenone was tested for metabolic
stability for 6 h with or without 40 µM 5 (Figure 4). A significant reduction of idebenone metabolism
by 40 µM 5 was observed from 20 µM idebenone onward. Not surprisingly, 5 was found to be stable,
as described in combination with all concentrations of idebenone (Figure S6). These results suggested
that 5 inhibited metabolic enzymes and could be used in combination with idebenone as a polytherapy
alternative to overcome its poor stability reported in vivo [15,18]. Future studies will need to address
the type of inhibition and to identify the specific enzyme that is inhibited.
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Figure 4. Reduced idebenone metabolism in the presence of the L-phenylalanine derivative 5. Data was
expressed as mean ± SEM from three independent experiments, with 4 data points each. Non-linear
fits and two-way ANOVA were performed for comparisons between with or without 5 supplemented:
*** p < 0.001, * p < 0.033.
4. Conclusions
A library of novel short-chain naphthoquinones was designed to support the discovery of drug
candidates to protect against mitochondrial dysfunction [11]. From this library, 16 compounds showed
significantly improved cytoprotective activity under conditions of mitochondrial dysfunction. We
presented new methods to study the metabolic stability of our novel SCQs in vitro. Our method
is characterized by high recovery rates, due to a simple precipitation procedure that eliminated
interferences during RP-LC analysis. The methods also provided quick and reliable results in an
accelerated manner within a typical working day. This allowed us to mimic the metabolic conversion
of SCQs in vitro in a manner comparable to their metabolic conversion in vivo. Among 16 new
SCQs tested, 15 showed significant metabolic stability compared to the clinically used benzoquinone
idebenone. Furthermore, structure-metabolic stability relationships, metabolic conversions and
inhibition of idebenone metabolism were addressed. Overall, these methods and results not only assist
to anticipate drug behavior in vivo in terms of their pharmacokinetic properties and metabolism but
also provide essential insights for future drug design, prodrug therapy and polytherapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/13/2/29/s1,
Table S1: Analytical figures of merit for the RP-LC of 16 new short-chain quinones (SCQs) and the clinically used
benzoquinone idebenone for the metabolic stability study, Figure S1: Metabolic conversion of the reference SCQ
idebenone over 6 h by different cell densities, Figure S2: Exemplary chromatograms of SCQ peaks detected after 2
h, 4 h or 6 h metabolism, Figure S3: Linear responses of idebenone to injection volumes between 2–20 µL, Figure
S4: Linear responses of 16 new SCQs and the reference benzoquinone idebenone between 1–10 µM, Figure S5:
Exemplary mass spectrometry chromatograms for the metabolic conversion from the L-phenylalaninol derivative
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3 to the L-phenylalanine derivative 5, Figure S6: Superior metabolic stability of the L-phenylalanine derivative 5
over 6 h in combination with all concentration series of the reference SCQ idebenone.
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